ABOUT THE SPEAKER
Seth Berkley - Vaccine visionary
Epidemiologist Seth Berkley is leading the charge to make sure vaccines are available to everyone, including those living in the developing world.

Why you should listen

Seth Berkley is an epidemiologist and the CEO of Gavi, the Vaccine Alliance, the global health organization protecting lives by improving access to vaccines in developing countries. Seth joined Gavi in 2011 in a period of rapid acceleration of Gavi’s programs. Now, with more than half a billion children immunized, he is leading Gavi’s efforts to reach a further 300 million children in the next five years and build sustainability into country immunization programs. Prior to Gavi, he spearheaded the development of vaccines for HIV as founder and CEO of the International AIDS Vaccine Initiative.

More profile about the speaker
Seth Berkley | Speaker | TED.com
TED2015

Seth Berkley: The troubling reason why vaccines are made too late ... if they're made at all

Filmed:
1,053,228 views

It seems like we wait for a disastrous disease outbreak before we get serious about making a vaccine for it. Seth Berkley lays out the market realities and unbalanced risks behind why we aren't making vaccines for the world's biggest diseases.
- Vaccine visionary
Epidemiologist Seth Berkley is leading the charge to make sure vaccines are available to everyone, including those living in the developing world. Full bio

Double-click the English transcript below to play the video.

00:13
The child's symptoms begin
0
1063
2208
00:15
with mild fever, headache, muscle pains,
1
3295
3637
00:18
followed by vomiting and diarrhea,
2
6956
2087
00:21
then bleeding from the mouth,
nose and gums.
3
9067
4100
00:25
Death follows in the form of organ failure
from low blood pressure.
4
13603
5497
00:31
Sounds familiar?
5
19887
1197
00:33
If you're thinking this is Ebola,
6
21592
2599
00:36
actually, in this case, it's not.
7
24215
1877
00:38
It's an extreme form of dengue fever,
a mosquito-born disease
8
26576
5355
00:43
which also does not have
an effective therapy or a vaccine,
9
31955
4061
00:48
and kills 22,000 people each year.
10
36040
3259
00:52
That is actually twice
the number of people
11
40018
2876
00:54
that have been killed by Ebola
12
42918
2029
00:56
in the nearly four decades
that we've known about it.
13
44971
3039
01:00
As for measles, so much
in the news recently,
14
48740
3699
01:04
the death toll is actually tenfold higher.
15
52463
3822
01:09
Yet for the last year,
16
57578
1771
01:11
it has been Ebola that has stolen
all of the headlines and the fear.
17
59373
4741
01:17
Clearly, there is something
deeply rooted about it,
18
65059
2797
01:19
something which scares us
and fascinates us
19
67880
2879
01:22
more than other diseases.
20
70783
1572
01:24
But what is it, exactly?
21
72896
1594
01:27
Well, it's hard to acquire Ebola,
22
75357
2229
01:29
but if you do, the risk
of a horrible death is high.
23
77610
3477
01:33
Why?
24
81697
1152
01:34
Because right now, we don't have any
effective therapy or vaccine available.
25
82873
4816
01:40
And so, that's the clue.
26
88133
2143
01:43
We may have it someday.
27
91022
1630
01:45
So we rightfully fear Ebola,
28
93453
3327
01:48
because it doesn't kill
as many people as other diseases.
29
96804
4418
01:53
In fact, it's much less transmissible
than viruses such as flu or measles.
30
101246
6000
01:59
We fear Ebola because of the fact
that it kills us and we can't treat it.
31
107270
5818
02:05
We fear the certain inevitability
that comes with Ebola.
32
113112
3388
02:08
Ebola has this inevitability
that seems to defy modern medical science.
33
116524
5578
02:14
But wait a second, why is that?
34
122507
1754
02:16
We've known about Ebola since 1976.
35
124705
2902
02:20
We've known what it's capable of.
36
128036
2072
02:22
We've had ample opportunity to study it
37
130132
2630
02:24
in the 24 outbreaks that have occurred.
38
132786
2388
02:27
And in fact, we've actually had
vaccine candidates available now
39
135491
4476
02:31
for more than a decade.
40
139991
1357
02:33
Why is that those vaccines
are just going into clinical trials now?
41
141856
4439
02:38
This goes to the fundamental
problem we have
42
146930
2834
02:41
with vaccine development
for infectious diseases.
43
149788
3004
02:45
It goes something like this:
44
153197
1759
02:47
The people most at risk for these diseases
45
155983
2803
02:50
are also the ones least able
to pay for vaccines.
46
158810
4159
02:55
This leaves little in the way
of market incentives
47
163858
3399
02:59
for manufacturers to develop vaccines,
48
167281
2964
03:02
unless there are large numbers of people
who are at risk in wealthy countries.
49
170269
4720
03:07
It's simply too commercially risky.
50
175522
2380
03:11
As for Ebola, there is absolutely
no market at all,
51
179244
4164
03:15
so the only reason we have two vaccines
in late-stage clinical trials now,
52
183432
5628
03:21
is actually because
of a somewhat misguided fear.
53
189084
2664
03:24
Ebola was relatively ignored
54
192520
3224
03:27
until September 11
and the anthrax attacks,
55
195768
4541
03:32
when all of a sudden,
people perceived Ebola
56
200333
2534
03:34
as, potentially, a bioterrorism weapon.
57
202891
2173
03:37
Why is it that the Ebola vaccine
wasn't fully developed at this point?
58
205485
4122
03:42
Well, partially, because
it was really difficult --
59
210167
2596
03:44
or thought to be difficult --
to weaponize the virus,
60
212787
2649
03:47
but mainly because
of the financial risk in developing it.
61
215460
5125
03:53
And this is really the point.
62
221028
1794
03:55
The sad reality is, we develop vaccines
63
223718
2520
03:58
not based upon the risk
the pathogen poses to people,
64
226262
3872
04:02
but on how economically risky it is
to develop these vaccines.
65
230158
4110
04:06
Vaccine development
is expensive and complicated.
66
234887
2909
04:09
It can cost hundreds
of millions of dollars
67
237820
2071
04:11
to take even a well-known antigen
and turn it into a viable vaccine.
68
239915
4308
04:17
Fortunately for diseases like Ebola,
69
245001
2454
04:19
there are things we can do
to remove some of these barriers.
70
247479
3390
04:23
The first is to recognize
when there's a complete market failure.
71
251385
3548
04:27
In that case, if we want vaccines,
72
255314
3034
04:30
we have to provide incentives
or some type of subsidy.
73
258372
5009
04:36
We also need to do a better job
at being able to figure out
74
264197
4340
04:40
which are the diseases
that most threaten us.
75
268561
2358
04:43
By creating capabilities within countries,
we then create the ability
76
271260
4915
04:48
for those countries to create
epidemiological and laboratory networks
77
276199
4617
04:52
which are capable of collecting
and categorizing these pathogens.
78
280840
4269
04:58
The data from that then can be used
79
286117
2262
05:00
to understand the geographic
and genetic diversity,
80
288403
3279
05:03
which then can be used
to help us understand
81
291706
2636
05:06
how these are being changed
immunologically,
82
294366
3643
05:10
and what type of reactions they promote.
83
298033
2324
05:13
So these are the things that can be done,
84
301198
2327
05:15
but to do this, if we want to deal
with a complete market failure,
85
303549
3684
05:19
we have to change the way
we view and prevent infectious diseases.
86
307257
5424
05:24
We have to stop waiting
until we see evidence
87
312705
4187
05:28
of a disease becoming a global threat
before we consider it as one.
88
316916
4804
05:34
So, for Ebola,
89
322617
2239
05:36
the paranoid fear
of an infectious disease,
90
324880
3891
05:40
followed by a few cases
transported to wealthy countries,
91
328795
4722
05:45
led the global community to come together,
92
333541
2600
05:48
and with the work
of dedicated vaccine companies,
93
336165
3505
05:51
we now have these:
94
339694
1666
05:54
Two Ebola vaccines in efficacy trials
in the Ebola countries --
95
342465
6007
06:00
(Applause)
96
348496
5505
06:06
and a pipeline of vaccines
that are following behind.
97
354025
3984
06:10
Every year, we spend billions of dollars,
98
358763
3092
06:13
keeping a fleet of nuclear submarines
permanently patrolling the oceans
99
361879
5073
06:18
to protect us from a threat
that almost certainly will never happen.
100
366976
3991
06:23
And yet, we spend virtually nothing
101
371527
2936
06:26
to prevent something as tangible
and evolutionarily certain
102
374487
5027
06:31
as epidemic infectious diseases.
103
379538
2178
06:35
And make no mistake about it --
it's not a question of "if," but "when."
104
383009
3895
06:38
These bugs are going to continue to evolve
105
386928
2912
06:41
and they're going to threaten the world.
106
389864
2003
06:44
And vaccines are our best defense.
107
392280
2344
06:47
So if we want to be able to prevent
epidemics like Ebola,
108
395108
4309
06:51
we need to take on the risk
of investing in vaccine development
109
399441
4446
06:55
and in stockpile creation.
110
403911
2038
06:58
And we need to view this, then,
as the ultimate deterrent --
111
406760
3625
07:02
something we make sure is available,
112
410409
3120
07:05
but at the same time,
praying we never have to use it.
113
413553
3639
07:09
Thank you.
114
417621
1151
07:10
(Applause)
115
418796
4278

▲Back to top

ABOUT THE SPEAKER
Seth Berkley - Vaccine visionary
Epidemiologist Seth Berkley is leading the charge to make sure vaccines are available to everyone, including those living in the developing world.

Why you should listen

Seth Berkley is an epidemiologist and the CEO of Gavi, the Vaccine Alliance, the global health organization protecting lives by improving access to vaccines in developing countries. Seth joined Gavi in 2011 in a period of rapid acceleration of Gavi’s programs. Now, with more than half a billion children immunized, he is leading Gavi’s efforts to reach a further 300 million children in the next five years and build sustainability into country immunization programs. Prior to Gavi, he spearheaded the development of vaccines for HIV as founder and CEO of the International AIDS Vaccine Initiative.

More profile about the speaker
Seth Berkley | Speaker | TED.com